Cellenkos, Inc.

About

Cellenkos, Inc. is a clinical-stage biotechnology company based in Houston, Texas. Founded in 2016, the company specializes in developing and commercializing allogeneic T regulatory cell (Treg) therapies aimed at treating rare inflammatory diseases and autoimmune disorders. Cellenkos utilizes a proprietary umbilical cord blood Treg cell therapy platform licensed from MD Anderson Cancer Center. The company's CRANE® technology platform focuses on T regulatory cells that do not require HLA or ABO matching, allowing for tailored treatments that can expand within the body and restore immune balance. Cellenkos manufactures its products at scale from a single cord blood unit and cryopreserves them for long-term storage. Their clinical pipeline includes therapies for conditions such as bone marrow failure, COVID-associated acute respiratory distress syndrome, Amyotrophic Lateral Sclerosis (ALS), and myelofibrosis, with ongoing research into additional applications like autism spectrum disorder and Alzheimer's disease. Cellenkos collaborates with leading research institutions to advance its innovative therapies.